{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:56:38Z","timestamp":1767902198193,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00115-022-01403-1","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T10:03:44Z","timestamp":1666778624000},"page":"306-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Konsensusstatement der Migr\u00e4ne- und Kopfschmerzgesellschaften (DMKG, \u00d6KSG & SKG) zur Therapiedauer der medikament\u00f6sen Migr\u00e4neprophylaxe","Consensus statement of the migraine and headache societies (DMKG, \u00d6KSG, and SKG) on the duration of pharmacological  migraine prophylaxis"],"prefix":"10.1007","volume":"94","author":[{"given":"Gudrun","family":"Go\u00dfrau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"F\u00f6rderreuther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Ruscheweyh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Ruschil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"Sprenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Kamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Freilinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Neeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Malzacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Gehring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Kraya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Dresler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph J.","family":"Schankin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas R.","family":"Gantenbein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Br\u00f6ssner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Zebenholzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charly","family":"Gaul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim P.","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"issue":"5","key":"1403_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00482-017-0214-1","volume":"31","author":"P Kropp","year":"2017","unstructured":"Kropp\u00a0P, Meyer\u00a0B, Dresler\u00a0T, Fritsche\u00a0G, Gaul\u00a0C, Niederberger\u00a0U et\u00a0al (2017) Relaxation techniques and behavioural therapy for the treatment of migraine: Guidelines from the German Migraine and Headache Society. Schmerz 31(5):433\u2013447. https:\/\/doi.org\/10.1007\/s00482-017-0214-1","journal-title":"Schmerz"},{"issue":"1","key":"1403_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner\u00a0TJ, Stovner\u00a0LJ, Jensen\u00a0R, Uluduz\u00a0D, Katsarava\u00a0Z (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J\u00a0Headache Pain 21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0","journal-title":"J Headache Pain"},{"issue":"10","key":"1403_CR3","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/head.13202","volume":"57","author":"JH Ford","year":"2017","unstructured":"Ford\u00a0JH, Jackson\u00a0J, Milligan\u00a0G, Cotton\u00a0S, Ahl\u00a0J, Aurora\u00a0SK (2017) A real-world analysis of migraine: A cross-sectional study of disease burden and treatment patterns. Headache 57(10):1532\u20131544. https:\/\/doi.org\/10.1111\/head.13202","journal-title":"Headache"},{"issue":"4","key":"1403_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/head.14289","volume":"62","author":"L Harris","year":"2022","unstructured":"Harris\u00a0L, L\u2019Italien\u00a0G, Kumar\u00a0A, Seelam\u00a0P, LaVallee\u00a0C, Coric\u00a0V et al (2022) Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States. Headache 62(4):473\u2013481. https:\/\/doi.org\/10.1111\/head.14289","journal-title":"Headache"},{"key":"1403_CR5","unstructured":"DMKG (2022) Mehr Kopfschmerzexpertise gew\u00fcnscht. https:\/\/www.attacke-kopfschmerzen.de\/news\/meldungen\/87-mehr-kopfschmerzexpertise-gewuenscht. Zugegriffen: 30.03.2022"},{"key":"1403_CR6","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"H-CGC Diener","year":"2018","unstructured":"Diener\u00a0H\u2011CGC, Kropp\u00a0P et al (2018) Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne. In: S1-Leitlinie. Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie (www.dgn.org\/leitlinien (abgerufen am 11.04.2022))"},{"key":"1403_CR7","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"H-C Diener","year":"2019","unstructured":"Diener\u00a0H\u2011C (2019) MAea. Prophylaxe der Migr\u00e4ne mit monoklonalen Antik\u00f6rpern gegen CGRP oder den CGRP-Rezeptor, Erg\u00e4nzung der S1-Leitlinie Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie (www.dgn.org\/leitlinien (abgerufen am 06.04.2022))"},{"issue":"1","key":"1403_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","volume":"22","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst\u00a0F, Van Deun\u00a0L, Van Dycke\u00a0A, Paemeleire\u00a0K, Reuter\u00a0U, Schoenen\u00a0J et\u00a0al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J\u00a0Headache Pain 22(1):128. https:\/\/doi.org\/10.1186\/s10194-021-01335-2","journal-title":"J Headache Pain"},{"issue":"1","key":"1403_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano\u00a0D, Lipton\u00a0RB, Scher\u00a0AI, Reed\u00a0ML, Stewart\u00a0WBF, Adams\u00a0AM et\u00a0al (2017) Fluctuations in episodic and chronic migraine status over the course of 1\u00a0year: implications for diagnosis, treatment and clinical trial design. J\u00a0Headache Pain 18(1):101. https:\/\/doi.org\/10.1186\/s10194-017-0787-1","journal-title":"J Headache Pain"},{"issue":"6","key":"1403_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp\u00a0Z, Dodick\u00a0DW, Varon\u00a0SF, Gillard\u00a0P, Hansen\u00a0RN, Devine\u00a0EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35(6):478\u2013488. https:\/\/doi.org\/10.1177\/0333102414547138","journal-title":"Cephalalgia"},{"issue":"4","key":"1403_CR11","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld\u00a0AM, Bloudek\u00a0LM, Becker\u00a0WJ, Buse\u00a0DC, Varon\u00a0SF, Maglinte\u00a0GA et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53(4):644\u2013655. https:\/\/doi.org\/10.1111\/head.12055","journal-title":"Headache"},{"issue":"7","key":"1403_CR12","doi-asserted-by":"publisher","first-page":"e0130733","DOI":"10.1371\/journal.pone.0130733","volume":"10","author":"JL Jackson","year":"2015","unstructured":"Jackson\u00a0JL, Cogbill\u00a0E, Santana-Davila\u00a0R, Eldredge\u00a0C, Collier\u00a0W, Gradall\u00a0A et al (2015) A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS ONE 10(7):e130733. https:\/\/doi.org\/10.1371\/journal.pone.0130733","journal-title":"PLoS ONE"},{"issue":"3","key":"1403_CR13","doi-asserted-by":"publisher","first-page":"e0212785","DOI":"10.1371\/journal.pone.0212785","volume":"14","author":"JL Jackson","year":"2019","unstructured":"Jackson\u00a0JL, Kuriyama\u00a0A, Kuwatsuka\u00a0Y, Nickoloff\u00a0S, Storch\u00a0D, Jackson\u00a0W et al (2019) Beta-blockers for the prevention of headache in adults, a\u00a0systematic review and meta-analysis. PLoS ONE 14(3):e212785. https:\/\/doi.org\/10.1371\/journal.pone.0212785","journal-title":"PLoS ONE"},{"key":"1403_CR14","doi-asserted-by":"publisher","first-page":"CD003225","DOI":"10.1002\/14651858.CD003225.pub2","volume":"2","author":"K Linde","year":"2004","unstructured":"Linde\u00a0K, Rossnagel\u00a0K (2004) Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2:CD3225. https:\/\/doi.org\/10.1002\/14651858.CD003225.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"1403_CR15","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S1474-4422(07)70272-7","volume":"6","author":"HC Diener","year":"2007","unstructured":"Diener\u00a0HC, Agosti\u00a0R, Allais\u00a0G, Bergmans\u00a0P, Bussone\u00a0G, Davies\u00a0B et al (2007) Cessation versus continuation of 6\u2011month migraine preventive therapy with topiramate (PROMPT): A\u00a0randomised, double-blind, placebo-controlled trial. Lancet Neurol 6(12):1054\u20131062. https:\/\/doi.org\/10.1016\/S1474-4422(07)70272-7","journal-title":"Lancet Neurol"},{"issue":"1","key":"1403_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1046\/j.1468-2982.1986.0601007.x","volume":"6","author":"PS Sorensen","year":"1986","unstructured":"Sorensen\u00a0PS, Hansen\u00a0K, Olesen\u00a0J (1986) A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia 6(1):7\u201314. https:\/\/doi.org\/10.1046\/j.1468-2982.1986.0601007.x","journal-title":"Cephalalgia"},{"issue":"1","key":"1403_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2165\/00003495-198427010-00002","volume":"27","author":"B Holmes","year":"1984","unstructured":"Holmes\u00a0B, Brogden\u00a0RN, Heel\u00a0RC, Speight\u00a0TM, Avery\u00a0GS (1984) Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic. Drugs 27(1):6\u201344. https:\/\/doi.org\/10.2165\/00003495-198427010-00002","journal-title":"Drugs"},{"issue":"5","key":"1403_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1046\/j.1468-2982.1996.1605337.x","volume":"16","author":"A Nuti","year":"1996","unstructured":"Nuti\u00a0A, Lucetti\u00a0C, Pavese\u00a0N, Dell\u2019Agnello\u00a0G, Rossi\u00a0G, Bonuccelli\u00a0U (1996) Long-term follow-up after flunarizine or nimodipine discontinuation in migraine patients. Cephalalgia 16(5):337\u2013340. https:\/\/doi.org\/10.1046\/j.1468-2982.1996.1605337.x","journal-title":"Cephalalgia"},{"issue":"Suppl 8","key":"1403_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/03331024880080S804","volume":"8","author":"JM Martinez-Lage","year":"1988","unstructured":"Martinez-Lage\u00a0JM (1988) Flunarizine (Sibelium) in the prophylaxis of migraine. An open, long-term, multicenter trial. Cephalalgia 8(Suppl 8):15\u201320. https:\/\/doi.org\/10.1177\/03331024880080S804","journal-title":"Cephalalgia"},{"issue":"6","key":"1403_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1046\/j.1468-2982.1991.1106251.x","volume":"11","author":"C Wober","year":"1991","unstructured":"Wober\u00a0C, Wober-Bingol\u00a0C, Koch\u00a0G, Wessely\u00a0P (1991) Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia 11(6):251\u2013256. https:\/\/doi.org\/10.1046\/j.1468-2982.1991.1106251.x","journal-title":"Cephalalgia"},{"key":"1403_CR21","unstructured":"Fachinformation Flunarizin. (7. Apr. 2019 ). https:\/\/www.abz.de\/assets\/products\/de\/label\/Flunarizin-CT%205%20mg%20Hartkapseln%20-%202.pdf?pzn=7320564. Zugegriffen: 30.03.2022"},{"key":"1403_CR22","unstructured":"https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Zulassung\/BereitsZugelAM\/offlabel\/Bewertungen\/Valproinsaeure_Addendum-3_08-11-2021.pdf?__blob=publicationFile. Zugegriffen: 30.03.2022"},{"issue":"4","key":"1403_CR23","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1212\/wnl.44.4.647","volume":"44","author":"R Jensen","year":"1994","unstructured":"Jensen\u00a0R, Brinck\u00a0T, Olesen\u00a0J (1994) Sodium valproate has a\u00a0prophylactic effect in migraine without aura: a\u00a0triple-blind, placebo-controlled crossover study. Neurology 44(4):647\u2013651. https:\/\/doi.org\/10.1212\/wnl.44.4.647","journal-title":"Neurology"},{"issue":"1","key":"1403_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1526-4610.2010.01800.x","volume":"51","author":"JR Couch","year":"2011","unstructured":"Couch\u00a0JR, Amitriptyline Versus Placebo Study Group (2011) Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 51(1):33\u201351. https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01800.x","journal-title":"Headache"},{"issue":"1","key":"1403_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10194-020-01113-6","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello\u00a0R, Guerzoni\u00a0S, Baraldi\u00a0C, Evangelista\u00a0L, Frattale\u00a0I, Marini\u00a0C et al (2020) Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data. J\u00a0Headache Pain 21(1):40. https:\/\/doi.org\/10.1186\/s10194-020-01113-6","journal-title":"J Headache Pain"},{"key":"1403_CR26","doi-asserted-by":"publisher","first-page":"647995","DOI":"10.3389\/fneur.2021.647995","volume":"12","author":"C Baraldi","year":"2021","unstructured":"Baraldi\u00a0C, Ornello\u00a0R, Favoni\u00a0V, Sacco\u00a0S, Caponnetto\u00a0V, Pierangeli\u00a0G et al (2021) Chronic migraine and medication overuse headache worsening after OnabotulinumtoxinA withdrawn due to the severe acute respiratory syndrome-Coronavirus\u20112 pandemic. Front Neurol 12:647995. https:\/\/doi.org\/10.3389\/fneur.2021.647995","journal-title":"Front Neurol"},{"key":"1403_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10194-016-0634-9","volume":"17","author":"S Guerzoni","year":"2015","unstructured":"Guerzoni\u00a0S, Pellesi\u00a0L, Baraldi\u00a0C, Pini\u00a0LA (2015) Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. J\u00a0Headache Pain 17:48. https:\/\/doi.org\/10.1186\/s10194-016-0634-9","journal-title":"J Headache Pain"},{"issue":"10","key":"1403_CR28","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/0333102414561873","volume":"35","author":"E Cernuda-Morollon","year":"2015","unstructured":"Cernuda-Morollon\u00a0E, Ramon\u00a0C, Larrosa\u00a0D, Alvarez\u00a0R, Riesco\u00a0N, Pascual\u00a0J (2015) Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year? Cephalalgia 35(10):864\u2013868. https:\/\/doi.org\/10.1177\/0333102414561873","journal-title":"Cephalalgia"},{"issue":"8","key":"1403_CR29","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/head.13630","volume":"59","author":"J Ching","year":"2019","unstructured":"Ching\u00a0J, Tinsley\u00a0A, Rothrock\u00a0J (2019) Prognosis following discontinuation of OnabotulinumA therapy in \u201csuper-responding\u201d chronic migraine patients. Headache 59(8):1279\u20131285. https:\/\/doi.org\/10.1111\/head.13630","journal-title":"Headache"},{"key":"1403_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15260","author":"LF Iannone","year":"2022","unstructured":"Iannone\u00a0LF, Fattori\u00a0D, Benemei\u00a0S, Chiarugi\u00a0A, Geppetti\u00a0P, De Cesaris\u00a0F (2022) Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15260","journal-title":"Eur J Neurol"},{"key":"1403_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-05870-x","author":"S Guerzoni","year":"2022","unstructured":"Guerzoni\u00a0S, Baraldi\u00a0C, Pensato\u00a0U, Favoni\u00a0V, Lo Castro\u00a0F, Cainazzo\u00a0MM et al (2022) Chronic migraine evolution after 3\u00a0months from erenumab suspension: real-world-evidence-life data. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-022-05870-x","journal-title":"Neurol Sci"},{"issue":"1","key":"1403_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10194-022-01417-9","volume":"23","author":"B Raffaelli","year":"2022","unstructured":"Raffaelli\u00a0B, Terhart\u00a0M, Mecklenburg\u00a0J, Neeb\u00a0L, Overeem\u00a0LH, Siebert\u00a0A et al (2022) Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a\u00a03-month drug holiday: a\u00a0real-world experience. J\u00a0Headache Pain 23(1):40. https:\/\/doi.org\/10.1186\/s10194-022-01417-9","journal-title":"J Headache Pain"},{"issue":"1","key":"1403_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s10194-019-1018-8","volume":"20","author":"B Raffaelli","year":"2019","unstructured":"Raffaelli\u00a0B, Mussetto\u00a0V, Israel\u00a0H, Neeb\u00a0L, Reuter\u00a0U (2019) Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J\u00a0Headache Pain 20(1):66. https:\/\/doi.org\/10.1186\/s10194-019-1018-8","journal-title":"J Headache Pain"},{"issue":"6","key":"1403_CR34","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/head.13508","volume":"59","author":"VL Stauffer","year":"2019","unstructured":"Stauffer\u00a0VL, Wang\u00a0S, Voulgaropoulos\u00a0M, Skljarevski\u00a0V, Kovacik\u00a0A, Aurora\u00a0SK (2019) Effect of Galcanezumab following treatment cessation in patients with migraine: Results from 2 randomized phase 3 trials. Headache 59(6):834\u2013847. https:\/\/doi.org\/10.1111\/head.13508","journal-title":"Headache"},{"issue":"11\u201312","key":"1403_CR35","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/03331024211014616","volume":"41","author":"AR Gantenbein","year":"2021","unstructured":"Gantenbein\u00a0AR, Agosti\u00a0R, Gobbi\u00a0C, Flugel\u00a0D, Schankin\u00a0CJ, Viceic\u00a0D et al (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment\u2014A\u00a0real-life cohort study. Cephalalgia 41(11\u201312):1181\u20131186. https:\/\/doi.org\/10.1177\/03331024211014616","journal-title":"Cephalalgia"},{"issue":"4\u20135","key":"1403_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/03331024211046617","volume":"42","author":"B Raffaelli","year":"2022","unstructured":"Raffaelli\u00a0B, Terhart\u00a0M, Overeem\u00a0LH, Mecklenburg\u00a0J, Neeb\u00a0L, Steinicke\u00a0M et al (2022) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a\u00a0prospective, longitudinal cohort study. Cephalalgia 42(4\u20135):326\u2013334. https:\/\/doi.org\/10.1177\/03331024211046617","journal-title":"Cephalalgia"},{"issue":"1","key":"1403_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s10194-021-01368-7","volume":"22","author":"M Terhart","year":"2021","unstructured":"Terhart\u00a0M, Mecklenburg\u00a0J, Neeb\u00a0L, Overeem\u00a0LH, Siebert\u00a0A, Steinicke\u00a0M et al (2021) Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J\u00a0Headache Pain 22(1):158. https:\/\/doi.org\/10.1186\/s10194-021-01368-7","journal-title":"J Headache Pain"},{"issue":"8","key":"1403_CR38","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1007\/s10072-020-05022-z","volume":"42","author":"E De Matteis","year":"2021","unstructured":"De Matteis\u00a0E, Affaitati\u00a0G, Frattale\u00a0I, Caponnetto\u00a0V, Pistoia\u00a0F, Giamberardino\u00a0MA et al (2021) Early outcomes of migraine after erenumab discontinuation: data from a\u00a0real-life setting. Neurol Sci 42(8):3297\u20133303. https:\/\/doi.org\/10.1007\/s10072-020-05022-z","journal-title":"Neurol Sci"},{"issue":"1","key":"1403_CR39","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri\u00a0F, Brunelli\u00a0N, Messina\u00a0R, Costa\u00a0CM, Colombo\u00a0B, Torelli\u00a0P et al (2021) Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J\u00a0Headache Pain 22(1):154. https:\/\/doi.org\/10.1186\/s10194-021-01363-y","journal-title":"J Headache Pain"},{"issue":"12","key":"1403_CR40","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/14712598.2019.1671350","volume":"19","author":"B Raffaelli","year":"2019","unstructured":"Raffaelli\u00a0B, Neeb\u00a0L, Reuter\u00a0U (2019) Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther 19(12):1307\u20131317. https:\/\/doi.org\/10.1080\/14712598.2019.1671350","journal-title":"Expert Opin Biol Ther"},{"key":"1403_CR41","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3389\/fpsyt.2019.00504","volume":"10","author":"Y Pan","year":"2019","unstructured":"Pan\u00a0Y, Kinitz\u00a0T, Stapic\u00a0M, Nestoriuc\u00a0Y (2019) Minimizing drug adverse events by informing about the Nocebo effect-an experimental study. Front Psychiatry 10:504. https:\/\/doi.org\/10.3389\/fpsyt.2019.00504","journal-title":"Front Psychiatry"},{"key":"1403_CR42","unstructured":"SKG-Therapieempfehlungen f\u00fcr prim\u00e4re Kopfschmerzen (Brosch\u00fcre 2021)\n      https:\/\/www.headache.ch\/download\/Content_attachments\/FileBaseDoc\/SKG_Therapieempfehlungen_DE_19_WEB.pdfzugegriffen. Zugegriffen: 19.09.2022"},{"key":"1403_CR43","first-page":"13","volume":"1","author":"AR","year":"2013","unstructured":"AR, SPG (2013) Positive Nebenwirkungen in der Migr\u00e4netherapie. Schweiz Z Psychiatr Neurol 1:13\u201315","journal-title":"Schweiz Z Psychiatr Neurol"},{"issue":"2","key":"1403_CR44","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter\u00a0U, Ehrlich\u00a0M, Gendolla\u00a0A, Heinze\u00a0A, Klatt\u00a0J, Wen\u00a0S et al (2022) Erenumab versus topiramate for the prevention of migraine\u2014A\u00a0randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 42(2):108\u2013118. https:\/\/doi.org\/10.1177\/03331024211053571","journal-title":"Cephalalgia"},{"key":"1403_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2072","author":"Y Zhang","year":"2022","unstructured":"Zhang\u00a0Y, Xu\u00a0Y, Liu\u00a0S, Liang\u00a0J, Fan\u00a0S, Ding\u00a0M et al (2022) The Nocebo response in pharmacologic treatments of primary headache: A systematic review and meta-analysis. J\u00a0Clin Pharmacol. https:\/\/doi.org\/10.1002\/jcph.2072","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1403_CR46","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00115-018-0534-0","volume":"89","author":"R Ruscheweyh","year":"2018","unstructured":"Ruscheweyh\u00a0R, Forderreuther\u00a0S, Gaul\u00a0C, Gendolla\u00a0A, Holle-Lee\u00a0D, Jurgens\u00a0T et al (2018) Treatment of chronic migraine with botulinum neurotoxin A : Expert recommendations of the German Migraine and Headache Society. Nervenarzt 89(12):1355\u20131364. https:\/\/doi.org\/10.1007\/s00115-018-0534-0","journal-title":"Nervenarzt"},{"issue":"4\u20135","key":"1403_CR47","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/03331024211047454","volume":"42","author":"D Chowdhury","year":"2022","unstructured":"Chowdhury\u00a0D, Bansal\u00a0L, Duggal\u00a0A, Datta\u00a0D, Mundra\u00a0A, Krishnan\u00a0A et al (2022) TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. Cephalalgia 42(4\u20135):396\u2013408. https:\/\/doi.org\/10.1177\/03331024211047454","journal-title":"Cephalalgia"},{"issue":"4","key":"1403_CR48","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/head.14097","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton\u00a0RB, Cohen\u00a0JM, Galic\u00a0M, Seminerio\u00a0MJ, Yeung\u00a0PP, Aycardi\u00a0E et\u00a0al (2021) Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. Headache 61(4):662\u2013672. https:\/\/doi.org\/10.1111\/head.14097","journal-title":"Headache"},{"issue":"5","key":"1403_CR49","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1136\/jnnp-2020-324396","volume":"92","author":"M Lanteri-Minet","year":"2021","unstructured":"Lanteri-Minet\u00a0M, Goadsby\u00a0PJ, Reuter\u00a0U, Wen\u00a0S, Hours-Zesiger\u00a0P, Ferrari\u00a0MD et al (2021) Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2\u20134 preventives were not useful: results from the LIBERTY study. J\u00a0Neurol Neurosurg Psychiatry 92(5):466\u2013472. https:\/\/doi.org\/10.1136\/jnnp-2020-324396","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Supplement","key":"1403_CR50","first-page":"27","volume":"11","author":"AEE Ambrosini","year":"2020","unstructured":"Ambrosini\u00a0AEE, Pascual\u00a0J, Rettiganti\u00a0M, Stroud\u00a0C, Day\u00a0K, Ford\u00a0J (2020) Effects of galcanezumab on acute medication use and health care resource utilization in treatment-resistant migraine: Results from randomized, double blind, placebo-controlled clinical trial, conquer. Headache Med 11(Supplement):27 (https:\/\/headachemedicine.com.br\/index.php\/hm\/article\/view\/112)","journal-title":"Headache Med"},{"key":"1403_CR51","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1796-21.2022","author":"SR Krimmel","year":"2022","unstructured":"Krimmel\u00a0SR, DeSouza\u00a0DD, Keaser\u00a0ML, Sanjanwala\u00a0BM, Cowan\u00a0RP, Lindquist\u00a0MA et\u00a0al (2022) Three dimensions of association link migraine symptoms and functional connectivity. J\u00a0Neurosci. https:\/\/doi.org\/10.1523\/JNEUROSCI.1796-21.2022","journal-title":"J Neurosci"},{"issue":"1","key":"1403_CR52","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco\u00a0S, Amin\u00a0FM, Ashina\u00a0M, Bendtsen\u00a0L, Deligianni\u00a0CI, Gil-Gouveia\u00a0R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update. J\u00a0Headache Pain 23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"issue":"5","key":"1403_CR53","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp\u00a0Z, Dodick\u00a0DW, Varon\u00a0SF, Chia\u00a0J, Matthew\u00a0N, Gillard\u00a0P et\u00a0al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. Cephalalgia 37(5):470\u2013485. https:\/\/doi.org\/10.1177\/0333102416678382","journal-title":"Cephalalgia"},{"issue":"4\u20135","key":"1403_CR54","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/03331024211048765","volume":"42","author":"LH Overeem","year":"2022","unstructured":"Overeem\u00a0LH, Peikert\u00a0A, Hofacker\u00a0MD, Kamm\u00a0K, Ruscheweyh\u00a0R, Gendolla\u00a0A et al (2022) Effect of antibody switch in non-responders to a\u00a0CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study. Cephalalgia 42(4\u20135):291\u2013301. https:\/\/doi.org\/10.1177\/03331024211048765","journal-title":"Cephalalgia"}],"updated-by":[{"DOI":"10.1007\/s00115-022-01435-7","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000}}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-022-01403-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-022-01403-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-022-01403-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T13:03:30Z","timestamp":1681477410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-022-01403-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1403"],"URL":"https:\/\/doi.org\/10.1007\/s00115-022-01403-1","relation":{"erratum":[{"id-type":"doi","id":"10.1007\/s00115-022-01435-7","asserted-by":"object"}]},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"23 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00115-022-01435-7","URL":"https:\/\/doi.org\/10.1007\/s00115-022-01435-7","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Go\u00dfrau: Vortragshonorare, Beratert\u00e4tigkeit Teva, Lilly, Novartis, Hormosan, Lundbeck, IMPP, Forschungsf\u00f6rderung DFG, Novartis, Kosing-Stiftung, TU Dresden, Ehrenamtliche Vizepr\u00e4sidentin DMKG. S.\u00a0F\u00f6rderreuther: Vortragshonorare, Beratert\u00e4tigkeit: Sanofi, TEVA, Novartis, Eli Lilly. Beratert\u00e4tigkeit: Hormosan, Lundbeck, Vortragshonorare: Allergan\/Abbvie. R.\u00a0Ruscheweyh: Vortragshonorare, Beratert\u00e4tigkeit, Unterst\u00fctzung f\u00fcr Kongressreisen: Hormosan, Novartis, Lilly, Lundbeck, Pharm-Allergan, Teva. V.\u00a0Ruschil: Forschungsf\u00f6rderung von Novartis. T.\u00a0Sprenger: Vortragshonorare, Beratert\u00e4tigkeit: Actelion\/Janssen Cilag, Biogen Idec, Bristol Myers Squibb, Electrocore, Eli Lilly, Merck, Roche, Sanofi, Novartis, Teva; die Honorare der genannten Aktivit\u00e4ten erhielt vollumf\u00e4nglich der Arbeitgeber (DKD Helios Klinik Wiesbaden) von T.\u00a0Sprenger. D.\u00a0Lewis: Vortragshonorare, Beratert\u00e4tigkeit: Allergan Pharma , Hormosan Pharma, Lilly, Lundbeck, Novartis Pharma und TEVA-Ratiopharm. K.\u00a0Kamm: Vortragshonorare: Novartis, TEVA, Lundbeck. T.\u00a0Freilinger: Forschungsf\u00f6rderung: Electrocore, Novartis Lilly, DFG, BMBF, Universit\u00e4t T\u00fcbingen, Vortragst\u00e4tigkeit, Beratert\u00e4tigkeit: Novartis, Teva; Vortragst\u00e4tigkeit: Lilly, Bayer, UCB. L.\u00a0Neeb: Vortragshonorare, Beratert\u00e4tigkeit: Hormosan, Lilly, Novartis, TEVA, Allergan, Forschungsf\u00f6rderung: Innovationsfonds, TEVA, Lilly. V.\u00a0Malzacher: keine Interessenkonflikte, Ehrenamtlicher Schatzmeister DMKG. U.\u00a0Meier: Vortragshonorare, Beratert\u00e4tigkeit: Biogen, BMS, Gaia AG, Janssen, Merck Healthcare Germany, Novartis, Roche. K.\u00a0Gehring: Vortragshonorare, Beratert\u00e4tigkeit: Janssen, Novartis, Merck, Roche, Hexal, Vorsitzender BVDN. T.\u00a0Kraya: Vortrags- oder Beratert\u00e4tigkeit: Allergan Pharma, Hormosan Pharma, Gr\u00fcnenthal, Lilly, Novartis, Teva, Forschungsf\u00f6rderung, DFG, Innovationsfonds, BMBF, Allergan Pharma, Hormosan Pharma, Gr\u00fcnenthal, Lilly, Novartis, Teva, Ehrenamtlicher 2.\u00a0Vizepr\u00e4sident DMKG. T.\u00a0Dresler: Vortragshonorare, Beratert\u00e4tigkeit: Novartis, Teva, Hormosan. C.J.\u00a0Schankin: Vortragshonorare, Beratert\u00e4tigkeit, \u00dcbernahme von Reisekosten: Eli Lilly, Novartis, TEVA Pharmaceuticals, Lundbeck, Allergan, Almirall, Amgen, MindMed, Gr\u00fcnenthal; Teilzeitanstellung: Zynnon; Forschungsf\u00f6rderung: DMKG, Eye on Vision Foundation, Baasch Medicus Foundation. A.R.\u00a0Gantenbein: Vortragshonorare, Beratert\u00e4tigkeit: Allergan\/Abbvie, Almirall, BioMed, Curatis, Eli Lilly, Gr\u00fcnenthal, Lundbeck, Neurolite, Novartis\/Amgen, Sanofi, Teva\/Mepha sowie f\u00fcr Aus- und Weiterbildung von medinform, MedScape, SIM. G.\u00a0Br\u00f6ssner: Vortragst\u00e4tigkeit: Lilly, TEVA, Novartis, Gr\u00fcnenthal; Beratungst\u00e4tigkeit: Lilly, TEVA, Novartis, Pfizer, Abbvie, Lundbeck; Forschungsf\u00f6rderung: TEVA. K.\u00a0Zebenholzer: Vortragshonorare, Beratert\u00e4tigkeit: Lundbeck, Gr\u00fcnenthal, Novartis Pharma, Eli Lilly, Teva Ratiopharm, Abbvie, Pfizer, MedAhead, vielgesundheit.at, Stada, MedMedia, Sanofi Genzyme; \u00dcbernahme von Reisekosten, Kongressgeb\u00fchren: MedAhead, \u00d6sterreichische Gesellschaft f\u00fcr Neurologie, \u00d6sterreichische Kopfschmerzgesellschaft, Eli Lilly, Sanofi Genzyme, Bristol Myers Squibb\/Celgene. H.\u2011C.\u00a0Diener: Vortragshonorare, Beratert\u00e4tigkeit: Abbvie, Ipsen Pharma, Lilly, Lundbeck, Novartis, Pfizer, TEVA und Weber & Weber; Forschungsf\u00f6rderung: DFG, BMBF. C.\u00a0Gaul: Abbvie-Allergan Pharma, TEVA-Ratiopharm, Lilly, Novartis Pharma, Hormosan Pharma, Weber & Weber, Lundbeck, Perfood und Gr\u00fcnenthal; Forschungsf\u00f6rderung: DFG; Ehrenamtlicher Generalsekret\u00e4r der DMKG. T.P.\u00a0J\u00fcrgens: Vortragshonorare, Beratert\u00e4tigkeit: Abbvie\/Allergan, Gr\u00fcnenthal, Hormosan, Lilly, Lundbeck, Novartis, Sanofi, TEVA; Tantiemen f\u00fcr Buchartikel von Elsevier und Springer; Forschungsf\u00f6rderung: Innovationsfonds, Europ\u00e4ische Union (EFRE), Novartis; Ehrenamtlicher Pr\u00e4sident der DMKG; Associate Editor Frontiers in Neurology, Mitglied Editorial Boards Journal of Headache and Pain.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}